Digestive Diseases and Sciences

, Volume 54, Issue 1, pp 89–96 | Cite as

siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine Chemosensitivity

  • Wen-Song Liu
  • Hai-Jiao Yan
  • Ren-Yi Qin
  • Rui Tian
  • Min Wang
  • Jian-Xin Jiang
  • Ming Shen
  • Cheng-Jian Shi
Original Article


Survivin is known to be overexpressed in various human malignancies, including pancreatic cancer, and to cause resistance to radiation and chemotherapy, so the regulation of this molecule could be a new strategy for treating pancreatic cancer. In our study, a short interfering RNA (siRNA) plasmid expression vector against survivin was constructed and transfected into human pancreatic cancer cell lines of Panc-1 and BxPC3. The expression of survivin mRNA and protein among the stable transfected cells and the untransfected cells was detected by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot, respectively. Tumor cell growth in vitro was assessed by trypan blue exclusion. The cell cycle distribution and cell apoptosis were measured by flow cytometry. The cytotoxicity assay was measured by the MTT test. Our results showed that survivin siRNA treatment caused a specific and profound decrease of survivin mRNA and protein that was associated with decreased cell growth, spontaneous apoptosis, and a specific G0/G1 arrest. Furthermore, the suppression of survivin can enhance the chemosensitivity of pancreatic cancer cells to gemcitabine significantly. We suggest that the RNAi against survivin gene strategy would be a potential approach to chemosensitization therapy in human pancreatic cancer.


Pancreatic cancer Chemosensitivity RNA interference Survivin 



We thank Jin Huang (Institute of Liver Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China) for the technical assistance. This work was supported by the National Natural Science Foundation of China, grant nos. 30471693 and 30600592.


  1. 1.
    Keighley MRB (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18:7–30. doi:10.1046/j.0953-0673.2003.01722.x PubMedCrossRefGoogle Scholar
  2. 2.
    Pino SM, Xiong HQ, McConkey D, Abbruzzese JL (2004) Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 6:119–125. doi:10.1007/s11894-004-0038-x PubMedCrossRefGoogle Scholar
  3. 3.
    El-Rayes BF, Philip PA (2003) A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 1:430–434PubMedGoogle Scholar
  4. 4.
    Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247:35–88. doi:10.1016/S0074-7696(05)47002-3 PubMedCrossRefGoogle Scholar
  5. 5.
    Lee MA, Park GS, Lee HJ, Jung JH, Kang JH, Hong YS, Lee KS, Kim DG, Kim SN (2005) Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 5:127. doi:10.1186/1471-2407-5-127 PubMedCrossRefGoogle Scholar
  6. 6.
    Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Fujimoto K, Wada M, Miyatake S, Imamura M (2004) Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136:443–448. doi:10.1016/j.surg.2004.05.023 PubMedCrossRefGoogle Scholar
  7. 7.
    Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271–278. doi: 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0PubMedCrossRefGoogle Scholar
  8. 8.
    Wang Y, Zhu H, Quan L, Zhou C, Bai J, Zhang G, Zhan Q, Xu N (2005) Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther 4:974–978PubMedCrossRefGoogle Scholar
  9. 9.
    Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M (2005) Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138:299–305. doi:10.1016/j.surg.2005.05.009 PubMedCrossRefGoogle Scholar
  10. 10.
    Song H, Xin XY, Xiao F, Wang DT, Yue QH, Han X (2008) Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol 136:83–89. doi:10.1016/j.ejogrb.2006.07.057 PubMedCrossRefGoogle Scholar
  11. 11.
    Liu F, Xie ZH, Cai GP, Jiang YY (2007) The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull 30:2279–2283. doi:10.1248/bpb.30.2279 PubMedCrossRefGoogle Scholar
  12. 12.
    Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP, Meye A (2006) Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 232:243–254. doi:10.1016/j.canlet.2005.02.027 PubMedCrossRefGoogle Scholar
  13. 13.
    Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99:4349–4354. doi:10.1073/pnas.072586399 PubMedCrossRefGoogle Scholar
  14. 14.
    Li H, Niederkorn JY, Neelam S, Alizadeh H (2006) Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res 83:176–182. doi:10.1016/j.exer.2005.11.024 PubMedCrossRefGoogle Scholar
  15. 15.
    Shinohara ET, Hallahan DE, Lu B (2004) The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biol Proced Online 6:250–256. doi:10.1251/bpo95 PubMedCrossRefGoogle Scholar
  16. 16.
    Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N (2002) A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 93:1057–1062PubMedGoogle Scholar
  17. 17.
    Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG, Zaffaroni N (2003) Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120:648–654. doi:10.1046/j.1523-1747.2003.12082.x PubMedCrossRefGoogle Scholar
  18. 18.
    Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ (2007) Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25:7955–7961PubMedCrossRefGoogle Scholar
  19. 19.
    Hannon GJ (2002) RNA interference. Nature 418:244–251. doi:10.1038/418244a PubMedCrossRefGoogle Scholar
  20. 20.
    Marx J (2000) Interfering with gene expression. Science 288:1370–1372. doi:10.1126/science.288.5470.1370 PubMedCrossRefGoogle Scholar
  21. 21.
    Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K (2003) RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 30:96–102. doi:10.1046/j.1440-1681.2003.03801.x PubMedCrossRefGoogle Scholar
  22. 22.
    Brantl S (2002) Antisense-RNA regulation and RNA interference. Biochim Biophys Acta 1575:15–25PubMedGoogle Scholar
  23. 23.
    Matta H, Hozayev B, Tomar R, Chugh P, Chaudhary PM (2003) Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2:206–210PubMedGoogle Scholar
  24. 24.
    Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553. doi:10.1126/science.1068999 PubMedCrossRefGoogle Scholar
  25. 25.
    Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22:2934–2947. doi:10.1093/emboj/cdg307 PubMedCrossRefGoogle Scholar
  26. 26.
    Lens SM, Vader G, Medema RH (2006) The case for Survivin as mitotic regulator. Curr Opin Cell Biol 18:616–622. doi:10.1016/j.ceb.2006.08.016 PubMedCrossRefGoogle Scholar
  27. 27.
    Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123. doi:10.1021/bi001603q PubMedCrossRefGoogle Scholar
  28. 28.
    Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547. doi:10.1016/S1471-4914(01)02243-2 PubMedCrossRefGoogle Scholar
  29. 29.
    Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR (2004) Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6:29–40PubMedGoogle Scholar
  30. 30.
    Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130–23140. doi:10.1074/jbc.M300957200 PubMedCrossRefGoogle Scholar
  31. 31.
    Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584. doi:10.1038/25141 PubMedCrossRefGoogle Scholar
  32. 32.
    Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA, Weiss RM (2007) Downregulation of survivin is associated with reductions in TNF receptors’ mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 25:678–684. doi:10.1080/07357900701600954 PubMedCrossRefGoogle Scholar
  33. 33.
    Gazzaniga P, Silvestri I, Gradilone A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Aglianò AM (2007) Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs 18:179–185. doi:10.1097/CAD.0b013e328010ef47 PubMedCrossRefGoogle Scholar
  34. 34.
    Chang Q, Liu ZR, Wang DY, Kumar M, Chen YB, Qin RY (2004) Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol 10:415–418PubMedGoogle Scholar
  35. 35.
    Zhang B, Pan JS, Liu JY, Han SP, Hu G, Wang B (2006) Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer. Methods Find Exp Clin Pharmacol 28:619–625. doi:10.1358/mf.2006.28.9.1003581 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Wen-Song Liu
    • 1
  • Hai-Jiao Yan
    • 2
  • Ren-Yi Qin
    • 1
  • Rui Tian
    • 1
  • Min Wang
    • 1
  • Jian-Xin Jiang
    • 1
  • Ming Shen
    • 1
  • Cheng-Jian Shi
    • 1
  1. 1.Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanPeople’s Republic of China
  2. 2.State Key Laboratory of Tumors, Cancer CenterSun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations